The combination of teclistamab and daratumumab produced a 71% overall response rate in patients with heavily pretreated multiple myeloma who had exhausted standard therapies. This bispecific antibody approach targets both BCMA and CD38 proteins simultaneously, offering a dual mechanism of immune system engagement against malignant plasma cells. The finding represents a meaningful advancement for patients facing limited treatment options in advanced disease stages. This dual-targeting strategy builds on the established efficacy of single-agent bispecific antibodies while potentially reducing resistance mechanisms that often emerge with monotherapy. The response durability and toxicity profile will determine whether this combination becomes standard care for relapsed cases. Multiple myeloma remains challenging to cure despite recent therapeutic advances, with most patients eventually developing resistance to available treatments. The ability to achieve meaningful responses in heavily pretreated populations suggests this approach could extend progression-free survival in a patient group with historically poor outcomes. However, the trial's relatively small size and short follow-up period mean longer-term efficacy and safety data will be crucial for regulatory approval and clinical adoption.